《新股表現》三葉草生物(02197.HK)暗盤低開逾10%報12元
根據輝立交易平臺顯示,明天掛牌的三葉草生物-B(02197.HK)暗盤低開逾10%報12元獲承接,現報12.28元,較上市價13.38元,低8.2%,成交10萬股。
三葉草生物於2007年成立,是一家處於臨牀試驗階段全球性生物技術公司,致力於爲傳染性疾病與癌症及自身免疫性疾病開發新型疫苗及生物治療候選產品。公司主要產品於各治療領域適應症分別爲COVID-19、惡性腹水及強直性脊柱炎。憑藉Trimer-Tag技術平臺成爲COVID-19疫苗開發企業,並已創制 出SCB-2019(核心產品之一)以應對SARS-CoV-2引起的COVID-19疫情。
是次來港上市共發售1.5億股,並引入包括OrbiMed、HHLR、淡馬錫及Rock Springs Capital等九家基石投資者合共認購8,052.55萬股;10%公開發售獲3.4倍超購,認購一手中籤率35%,股份以接近招股範圍(12.8-13.5元)上限定價,料淨籌約18.7億元,主要用於核心產品等相關產品研發、生產和商業化,以及用於公司管線中其他產品研發、生產及商業化等。上市聯席保薦人分別爲高盛及中金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.